Tarsus Pharmaceuticals Inc.’s recent filing unveils that its President/CEO and Board Chair Azamian Bobak R. unloaded Company’s shares for reported $0.14 million on Aug 23. In the deal valued at $17.23 per share,8,000 shares were sold. As a result of this transaction, Azamian Bobak R. now holds 902,106 shares worth roughly $ 14.56 million.
Then, Lin Elizabeth Yeu bought 9,506 shares, generating $159,701 in total proceeds. Upon buying the shares at $16.80, the Director now owns 15,866 shares.
Before that, Azamian Bobak R. sold 103,900 shares. Tarsus Pharmaceuticals Inc. shares valued at $2,078,984 were divested by the President/CEO and Board Chair at a price of $20.01 per share. As a result of the transaction, Azamian Bobak R. now holds 910,106 shares, worth roughly $14.69 million.
William Blair initiated its Tarsus Pharmaceuticals Inc. [TARS] rating to an Outperform in a research note published on Friday, July 18, 2023; the price target was $44. PT values the company’s stock at a premium of 63.32 to its Friday closing price.
Price Performance Review of TARS
On Friday, Tarsus Pharmaceuticals Inc. [NASDAQ:TARS] saw its stock jump 9.42% to $16.14. On the same session, the stock had its day’s lowest price of $14.82, but rose to a high of $16.24. Over the last five days, the stock has gained 0.56%. Tarsus Pharmaceuticals Inc. shares have risen nearly 10.10% since the year began. Nevertheless, the stocks have fallen -0.80% over the past one year. While a 52-week high of $25.25 was reached on 07/24/23, a 52-week low of $11.33 was recorded on 04/17/23. SMA at 50 days reached $17.92, while 200 days put it at $15.97. A total of 1.39 million shares were traded, compared to the trading of 0.36 million shares in the previous session.
Levels Of Support And Resistance For TARS Stock
The 24-hour chart illustrates a support level at 15.23, which if violated will result in even more drops to 14.31. On the upside, there is a resistance level at 16.65. A further resistance level may holdings at 17.15. The Relative Strength Index (RSI) on the 14-day chart is 45.76, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.13, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 51.58%. Stochastics %K at 18.66% indicates the stock is a buying.
How much short interest is there in Tarsus Pharmaceuticals Inc.?
A steep rise in short interest was recorded in Tarsus Pharmaceuticals Inc. stocks on Aug 30, 2023, growing by 0.71 million shares to a total of 4.51 million shares. Yahoo Finance data shows the prior-month short interest on Jul 30, 2023 was 3.8 million shares. There was a rise of 15.74%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 14.58% of the overall stock float, the days-to-cover ratio (short ratio) rose to 9.49.
According to FactSet, Tarsus Pharmaceuticals Inc.’s share price will average $46.63 in the next year, based on opinions of analysts polled by the firm. This is up nearly 222.03 percent from its previous closing price of $14.75. Analysts expect Tarsus Pharmaceuticals Inc. stock to reach the higher price of $60.00, while the lowest price estimate is $30.00. However, 8 analysts have rated TARS stock as a Buy in their predictions for 2023.